Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome

Table 3 Gene mutation features of 14 BCOR^MUT patients who accepted decitabine induction

Case no	Class	Cycles*	Response	BCOR mutations (VAF)	Concomitant mutations
1	RAEB-t	2	CR	BCOR/4/C925Y (51%)	DHX9; WT1
2	RAEB1	6	CR	BCOR/11/K1452X (60%)	DNMT3A; ROBO1; STAG2
3	RAEB2	4	CR	BCOR/8/R1323W (50%)	NPM1
4	CMML1	3	CR	BCOR/8/K1339N (33%)	ASXL1; MPL; TET2; UPF3A
5	RAEB1	4	mCR + HI	BCOR/4/A619fs (16%)	PHF6; RUNX1; TET2
6	RCMD	3	CR	BCOR/4/Y361fs (85%)	NRAS; ROBO1; RUNX1; U2AF1
7	RCMD	4	CR	BCOR/12/R1547*(49%)	ASXL1; RUNX1; SRSF2
8	RAEB1	4	mCR	BCOR/4/p819-819del (74%)	DNMT3A; IDH2; ROBO1; RUNX1
9	RAEB2	4	CR	BCOR/7/R1165X (29%)/11/C4326 + 1C > A (56%)	CEBPA; DNMT3A; RUNX1; STAG2;TET2; U2AF1
10	RAEB2	4	NR	BCOR/7/P1101fs (65%)	ITIH3
11	RAEB2	4	CR	BCOR/4/V912fs (32%)	ASXL1; STAG2
12	RCMD	2	NR	BCOR/4/P483L (48%)	DHX9; EZH2; IDH1; U2AF1
13	RAEB2	4	mCR + HI	BCOR/4/T738fs (46%)	EZH2; MPL; RUNX1
14	CMML2	2	NR	BCOR/4/P483L (100%)	None

^*The induced decitabine cycles number means the course number of continuously accepted decitabine treatment (the durations between courses did not exceed 30 days); For the CR achieved patients with less than 4 induced courses. (No. 1, 4 and 6), the patients rejected continuously decitabine usage by themselves

ISSN: 1868-7083